Potency assay design for adjuvanted recombinant proteins as malaria vaccines.
Many licensed vaccines are composed of live, attenuated or inactivated whole-cell microorganisms, or they comprise purified components from whole-cell extracts or culture supernatants. For some diseases, pathology is fairly well understood, and there may be known correlates of protection that provide obvious parameters for assessment of vaccine potency. However, this is not always the case, and some effective vaccines are routinely used even though the mechanisms or correlates of protection are unknown. Some more modern vaccine approaches employ purified recombinant proteins, based on molecules that appear on the surface of the pathogen. This is one of the strategies that has been adopted in the quest to develop a malaria vaccine. Use of these parasite antigens as vaccine candidates is supported by substantial epidemiological data, and some have demonstrated the ability to elicit protective responses in animal models of malaria infection. However, there is as yet no immunological correlate of protection and no functional assays or animal models that have demonstrated the ability to predict efficacy in humans. There is little precedence for the most appropriate and practical method for assessing potency of vaccines based on these recombinant molecules for malaria vaccines. This is likely because the majority of malaria vaccine candidates have only recently entered clinical evaluation. The PATH Malaria Vaccine Initiative (MVI) convened a panel with expertise in potency assay design from industry, governmental institutions, and regulatory bodies to discuss and review the rationale, available methods, and best approaches for assessing the potency of recombinant proteins, specifically for their use as malarial vaccines. The aim of this meeting was to produce a discussion document on the practical potency assessment of recombinant protein malaria vaccines, focusing on early phase potency assay development.
Giersing
Birgitte K
BK
PATH Malaria Vaccine Initiative (MVI), Bethesda, MD 20814, USA. bgiersing@malariavaccine.org
Dubovsky
Filip
F
Saul
Allan
A
Denamur
Francoise
F
Minor
Philip
P
Meade
Bruce
B
D000276:Adjuvants, Immunologic / Q000494:pharmacology*; D001681:Biological Assay; D017780:Malaria Vaccines / Q000276:immunology*; D011994:Recombinant Proteins / Q000494:pharmacology
D000276:Adjuvants, Immunologic; D017780:Malaria Vaccines; D011994:Recombinant Proteins